Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

Background Results from a phase III, randomized, double-blind, active comparator-controlled, parallel-group trial evaluating fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) found that a single-day, triple-antiemetic fosaprepitant regimen resulted in a significantl...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer Vol. 20; no. 1; pp. 918 - 10
Main Authors: Weinstein, Cindy, Jordan, Karin, Green, Stuart, Khanani, Saleem, Beckford-Brathwaite, Elizabeth, Vallejos, Waldimir, Pong, Annpey, Noga, Stephen J., Rapoport, Bernardo L.
Format: Journal Article
Language:English
Published: London BioMed Central 25.09.2020
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
ISSN:1471-2407, 1471-2407
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first